Skip to main content
SpringerLink
Log in

Comparative Adverse Effect Profiles of Platinum Drugs

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

An Erratum to this article was published on 01 March 1996

Summary

Since the discovery of the biologically active platinum complexes 30 years ago, 2 agents have become widely established in clinical oncology practice. Both cisplatin and carboplatin are platinum(II) complexes with 2 ammonia groups in the cis- position. However, they differ in their solubility, chemical reactivity, dichloride or alicyclic oxygenated leaving groups, pharmacokinetics and toxicology. Cisplatin causes severe renal tubular damage and reduces glomerular filtration, and requires concurrent saline hydration and mannitol diuresis to eliminate potentially lethal and unacceptable damage to the kidneys. Carboplatin, at conventional doses, causes no decrease in glomerular filtration and only minor transient elevations in urinary enzymes.

Cisplatin is the most emetic cancer drug in common use, while nausea and vomiting associated with carboplatin are moderately severe. Serotonin release from enterochromaffin gut mucosal cells and stimulation of serotonin 5-HT3-receptors mediates acute emesis. Selective inhibitors of the 5-HT3-receptor protect against cisplatin- and carboplatin-induced nausea and vomiting. Peripheral neurotoxicity is the most dose-limiting problem associated with cisplatin. Loss of vibration sense, paraesthesia and sensory ataxia comes on after several treatment cycles. Carboplatin, however, is relatively free from peripheral neurotoxicity. Audiometry shows cisplatin-induced ototoxicity in 75 to 100% of patients, which may be associated with tinnitus and hearing loss. Ototoxicity is rare with conventional dose carboplatin therapy. Monitoring hearing with audiograms may identify early signs before significant impairment occurs.

Cisplatin causes mild haematological toxicity to all 3 blood lineages. Haematological toxicity is dose-limiting for carboplatin, with thrombocytopenia being a greater problem than leucopenia. Although carboplatin is not toxic to the kidney, renal function markedly affects the severity of carboplatin-induced thrombocytopenia. The major clearance mechanism of cisplatin is irreversible binding in plasma and tissues, while carboplatin is cleared by glomerular filtration. Metabolism of cisplatin to aqua, amino acid and protein species is extensive, whereas carboplatin exists mainly as the free unchanged form. Strong relationships between carboplatin renal clearance, glomerular filtration rate, area under the plasma concentration-time curve (AUC) of filterable platinum and severity of thrombocytopenia have prompted dose adjustment according to renal function.

New analogues such as JM216 offer the potential advantages of oral administration and few nonhaematological toxicities. Analogues based on the diaminocyclohexane ligand have encountered problematic neurotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Pratt WB, Ruddon RW. The anticancer drugs. New York: Oxford University Press, 1979: 12–9

    Google Scholar 

  2. Abrams MJ, Murrer BA. Metal compounds in therapy and diagnosis. Science 1993; 261: 725–30

    PubMed  CAS  Google Scholar 

  3. Lissauer. Falle Von Leucaemie. Berl Klin Wochenschr 1865; 40: 403

    Google Scholar 

  4. Raven RW. The theory and practice of oncology: historical evolution and present principles. Carnforth: Parthenon Publishing Group, 1990: 243–56

    Google Scholar 

  5. Albert A. Selective toxicity: the physicochemical basis of therapy. 6th ed. London: Chapman and Hall, 1979: 180–236

    Google Scholar 

  6. Andrews PLR, Davis CJ, Bingham S, et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990; 68: 325–45

    PubMed  CAS  Google Scholar 

  7. Fowler BA, Mistry P, Goering PL. Mechanisms of metal-induced nephrotoxicity. In: Bach PH, Lock EA, editors. Nephrotoxicity in the experimental and clinical situation. Part 2. Dordrecht: Martinus Nijhoff, 1987: 659–81

    Google Scholar 

  8. McAlpine D, Araki S. Minamata disease an unusual neurological disorder caused by contaminated fish. Lancet 1958; ii: 629–31

    Google Scholar 

  9. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698

    PubMed  CAS  Google Scholar 

  10. Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agent. Nature 1969; 222: 385

    PubMed  CAS  Google Scholar 

  11. Horwich A. Current controversies in the management of testicular cancer. Eur J Cancer 1991; 27: 322–6

    PubMed  CAS  Google Scholar 

  12. McKeage MJ, Kelland LR. New platinum drugs. In: Neidle S, Waring M, editors. Molecular aspects of anticancer drug-DNA interactions. 2nd ed. Basingstoke: MacMillian Press, 1993: 169–212

    Google Scholar 

  13. Harrap KR. Platinum analogues: criteria for selection. In: Muggia FM, editor. Cancer chemotherapy. Massachusetts: Martinus Nijhoff, 1983: 171–217

    Google Scholar 

  14. Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichloro-diammineplatinum(II) to DNA. Chem Biol Interact 1980; 30: 151–69

    PubMed  CAS  Google Scholar 

  15. Borch RF. The platinum anti-tumour drugs. In: Powis G, Prough RA, eds. Metabolism and action of anti-cancer drugs. London: Taylor and Francis, 1987: 163–93

    Google Scholar 

  16. Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 1987; 87: 1153–81

    CAS  Google Scholar 

  17. Cheung YW, Cradock JC, Vishnuvajjala BR, et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hos Pharm 1987; 44: 124–30

    CAS  Google Scholar 

  18. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose m-platinum diammine dichloro amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81

    PubMed  CAS  Google Scholar 

  19. Harrap KR, Jones M, Wilkinson CR, et al. Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Cisplatin. New York: Academic Press Inc, 1980: 193–212

    Google Scholar 

  20. Siddik ZD, Newell DR, Boxall FE, et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987; 36: 1925–32

    PubMed  CAS  Google Scholar 

  21. Knox RJ, Friedlos F, Lydall DA, et al. Mechanisms of cytotoxicity of antitumour platinum drugs: evidence that cis-diamminedichloro and cis-diammine-(1,1-cyclobutano)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972–9

    PubMed  CAS  Google Scholar 

  22. Gore ME, Fryatt I, Wiltshaw E, et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60: 767–9

    PubMed  CAS  Google Scholar 

  23. Rossof AH, Slayton RE, Perlia CP. Preliminary experience with cis-diamminedichloroplatinum(II) (NSC 119875,CACP). Cancer 1972; 30: 1451–6

    PubMed  CAS  Google Scholar 

  24. Bitran JD, Desser RK, Billings AA, et al. Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer 1982; 49: 1784–8

    PubMed  CAS  Google Scholar 

  25. Dentino M, Luft FC, Yum MN, et al. Long term effect of cis-diamminedichloroplatinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274–81

    PubMed  CAS  Google Scholar 

  26. Daugaard G, Abildgaard U. Renal morbidity of chemotherapy. In: Plowman PN, McElwain TJ, Meadows AJ, editors. Complications of cancer management. Oxford: Butterworth-Heinemann, 1991: 213–31

    Google Scholar 

  27. Jones BR, Bhalla RB, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharm Ther 1980; 27: 557–62

    CAS  Google Scholar 

  28. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesaemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 1982; 66: 1767–9

    PubMed  CAS  Google Scholar 

  29. Bell DR, Woods RL, Levi JA. Cis-diamminedichloroplatinum-induced hypomagnesaemia and renal magnesium wasting. Eur J Cancer Clin Oncol 1985; 21: 287–90

    PubMed  CAS  Google Scholar 

  30. Hamilton CR, Bliss JM, Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol 1989; 25: 185–9

    PubMed  CAS  Google Scholar 

  31. Bissett D, Kunkeler L, Zwanenberg L, et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990; 62: 655–9

    PubMed  CAS  Google Scholar 

  32. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1989; 25: 1–9

    PubMed  CAS  Google Scholar 

  33. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 1362–71

    Google Scholar 

  34. Weiner MW, Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed Proc 1983; 42: 2974–8

    PubMed  CAS  Google Scholar 

  35. Reece PA, Stafford I, Russell J, et al. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 1986; 4: 1392–8

    PubMed  CAS  Google Scholar 

  36. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304–9

    PubMed  CAS  Google Scholar 

  37. Safirstein R, Winston J, Goldstein M, et al. Cisplatin nephrotoxicity. Am J Kidney Dis 1986; 8: 356–76

    PubMed  CAS  Google Scholar 

  38. Siddik ZH, Jones MR, Boxall FE, et al. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 1988; 21: 19–24

    PubMed  CAS  Google Scholar 

  39. Daley-Yates PT, McBrien DCH. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 1984; 33: 3063–70

    PubMed  CAS  Google Scholar 

  40. Uozumi J, Litterst Cl. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 1985; 15: 93–6

    PubMed  CAS  Google Scholar 

  41. Daley-Yates PT, McBrien DCH. The inhibition of renal ATPase by cisplatin and some bio-transformation products. Chem Biol Interact 1982; 40: 325–34

    PubMed  CAS  Google Scholar 

  42. Reed E, Litterst CL, Thill CC, et al. Cis-diamminedichloro-platinum(II)-DNA adduct formation in renal, gonadal, and tumour tissues of male and female rats. Cancer Res 1987; 47: 718–22

    PubMed  CAS  Google Scholar 

  43. Hannemann J, Duwe J, Baumann K. Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother Pharmacol 1991; 28: 427–33

    PubMed  CAS  Google Scholar 

  44. Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39: 1357–61

    PubMed  CAS  Google Scholar 

  45. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 31–5

    PubMed  CAS  Google Scholar 

  46. Daley-Yates PT, McBrien DCH. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985; 34: 2363–9

    PubMed  CAS  Google Scholar 

  47. Desimone PA, Yancey RS, Coupai JJ, et al. Effect of forced diuresis on the distribution and excretion via urine and bile of 195platinum cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979; 63: 951–60

    PubMed  CAS  Google Scholar 

  48. Comis RL. Cisplatin nephrotoxicity: the effect of dose, schedule, and hydration scheme. In: Prestayko AW, Crooke ST, Clarke SK, editors. Cisplatin: current status and new developments. Orlando: Academic Press, 1980: 485–94

    Google Scholar 

  49. Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomised trial. Br J Cancer 1986; 54: 19–23

    PubMed  CAS  Google Scholar 

  50. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21: 163–7

    PubMed  CAS  Google Scholar 

  51. Hargis JB, Anderson JR, Propert KJ, et al. Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a cancer and leukemia group B study. Cancer Chemother Pharmacol 1992; 39: 291–6

    Google Scholar 

  52. Stewart DJ, Mikhael NZ, Nanji AA, et al. Renal and hepatic concentrations of platinum: relationships to cisplatin time, dose and nephrotoxicity. J Clin Oncol 1985; 3: 1251–6

    PubMed  CAS  Google Scholar 

  53. Blumenreich MS, Woodcock TM, Jones M, et al. High-dose cisplatin in patients with advanced malignancies. Cancer 1985; 55: 1118–22

    PubMed  CAS  Google Scholar 

  54. Nanji AA, Stewart DJ, Mikhael NZ. Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 1986; 17: 274–6

    PubMed  CAS  Google Scholar 

  55. Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity correlation with plasma platinum concentrations. Am J Clin Oncol 1985; 8: 77–80

    PubMed  CAS  Google Scholar 

  56. Campbell AB, Kaiman SM, Jacobs C. Plasma platinum levels: relationships to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 169–72

    PubMed  CAS  Google Scholar 

  57. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies. Cancer Treat Rep 1978; 62: 693–8

    PubMed  CAS  Google Scholar 

  58. Salem PA, Jabboury KW, Khalil MF Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum(II) and cephalothin-gentamicin therapy. Oncology 1982; 39: 31–2

    PubMed  CAS  Google Scholar 

  59. Calvert AH, Harland SJ, Newell DR, et al. Early clinical trials with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140–7

    PubMed  CAS  Google Scholar 

  60. Mason MD, Nicholls J, Horwich A. The effect of carboplatin on renal function in patients with metastatic germ cell tumours. Br J Cancer 1991; 63: 630–3

    PubMed  CAS  Google Scholar 

  61. Gore ME, Calvert AH, Smith IE. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase dose escalation. Eur J Cancer Clin Oncol 1987; 23: 1391–7

    PubMed  CAS  Google Scholar 

  62. Shea TC, Flaherty M, Elias A, et al. A phase I and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–61

    PubMed  CAS  Google Scholar 

  63. Siddik ZH, Dible SE, Boxall FE, et al. Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: McBrien DCH, Slater TF, editors. Biochemical mechanisms of platinum antitumour drugs. Oxford: IRL Press Ltd, 1986: 171–98

    Google Scholar 

  64. Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203–8

    PubMed  CAS  Google Scholar 

  65. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramine: randomised trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 9: 905–9

    Google Scholar 

  66. Cubeddu LX, Hoffman IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatin-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691–7

    PubMed  CAS  Google Scholar 

  67. Du Bios A, Meerpohl HG, Vach W, et al. Course, patterns, and risk factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992; 28: 450–7

    Google Scholar 

  68. Harvey VJ, Evans BD, Mitchell PLR, et al. Reduction of carboplatin induced emesis by ondansetron. Br J Cancer 1991; 63: 942–4

    PubMed  CAS  Google Scholar 

  69. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agent. J Natl Cancer Inst 1991; 83: 613–20

    PubMed  CAS  Google Scholar 

  70. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; 66: 198–203

    PubMed  CAS  Google Scholar 

  71. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al. Efficacy of ondansetron (Gr 38032f) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–6

    PubMed  CAS  Google Scholar 

  72. Allan S, Smyth JF, Hay FG, et al. Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum. Cancer Res 1986; 46: 3569–73

    PubMed  CAS  Google Scholar 

  73. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide and dexamethasone. Cancer 1987; 60: 2816–22

    PubMed  CAS  Google Scholar 

  74. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytyptamine 3 (serotonin) antagonist ondansetron (Gr 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–21

    PubMed  CAS  Google Scholar 

  75. Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron a selective antagonist with intravenous metoclopramide in the prevention of nausea and vomiting associated with high dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721–8

    PubMed  CAS  Google Scholar 

  76. De Mulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared to high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40

    PubMed  Google Scholar 

  77. Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron and dexamethasone prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487–90

    PubMed  CAS  Google Scholar 

  78. Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19–24

    PubMed  CAS  Google Scholar 

  79. Hamers FPT, Gispen WH, Neijt JP. Neurotoxicity side-effects of cisplatin. Eur J Cancer 1991; 27: 372–6

    CAS  Google Scholar 

  80. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989; 16: 195–211

    PubMed  CAS  Google Scholar 

  81. Cavaletti G, Bogliun G, Marzorati L, et al. The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J Neurol 1991; 238: 371–4

    PubMed  CAS  Google Scholar 

  82. Elderson A, Van Der Hoop GR, Haanstra W, et al. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989; 93: 167–74

    PubMed  CAS  Google Scholar 

  83. Lipton RB, Galer BS, Dutcher JP, et al. Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer. Arch Neurol 1987; 44: 944–6

    PubMed  CAS  Google Scholar 

  84. Van Der Hoop GR, Van Der Burg MEL, Ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697–702

    PubMed  Google Scholar 

  85. Thompson SW, Davies LE, Kornfeld M, et al. Cisplatin neurotoxicity: clinical, electrophysiolic, morphologic and toxicologic studies. Cancer 1984; 54: 1269–75

    PubMed  CAS  Google Scholar 

  86. Cavaletti G, Tredici G, Marmiroli P, et al. Morphometric study of the sensory neuron and peripheral nerve changes by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992; 84: 364–71

    PubMed  CAS  Google Scholar 

  87. Gregg RW, Molepa JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurological tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795–803

    PubMed  CAS  Google Scholar 

  88. Terheggen PMAB, Van Der Hoop GR, Floot BGJ, et al. Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of neuroprotecting peptide ORG 766. Toxicol Appl Pharmacol 1989; 99: 334–43

    PubMed  CAS  Google Scholar 

  89. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126–7

    PubMed  CAS  Google Scholar 

  90. Mollman JE, Glover DJ, Hogan M, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–5

    PubMed  CAS  Google Scholar 

  91. Legha SS, Dimery IW. High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 1985; 3: 1373–8

    PubMed  CAS  Google Scholar 

  92. Gandara DR, Degregorio MW, Wold H, et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol 1986; 4: 1787–93

    PubMed  CAS  Google Scholar 

  93. Hamers FPT, Brakkee JH, Cavalletti E, et al. Reduced glutathi-one protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544–9

    PubMed  CAS  Google Scholar 

  94. Cascinu S, Cordelia L, Ferro ED, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomised double blind placebo-controlled trial. J Clin Oncol 1995; 1326-32

  95. Cavaletti G, Minoia C, Schieppati M, et al. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29: 771–6

    PubMed  CAS  Google Scholar 

  96. Abe R, Akiyoshi T, Tsuji H, et al. Protection of antiproliferative effect of cis-diamminedichloroplatinum(II) by sodium thiosulfate. Cancer Chemother Pharmacol 1986; 18: 98–100

    PubMed  CAS  Google Scholar 

  97. Gandara DR, Natihas WA, Adelson MD, et al. Randomised placebo-controlled multicentre evaluation of diethyldithio-carbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13: 490–6

    PubMed  CAS  Google Scholar 

  98. Van Der Hoop GR, Vechet CJ, Van Der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patient with ovarian cancer. N Engl J Med 1990; 322: 89–94

    PubMed  Google Scholar 

  99. Hovestadt A, Van Der Berg ME, Verbiest HB, et al. The course of neuropathy after cessation of cisplatin treatment combined with ORG2766 or placebo. J Neurol 1992; 239: 143–6

    PubMed  CAS  Google Scholar 

  100. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985; 12: 125–36

    PubMed  Google Scholar 

  101. Strauss M, Towfighi J, Lord S, et al. Cis-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554–9

    PubMed  CAS  Google Scholar 

  102. Waters GS, Ahmad M, Katasarkas A, et al. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 1991; 12: 91–102

    PubMed  CAS  Google Scholar 

  103. Aguilar-Markulis NV, Beckley S, Priore R, et al. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum(II) therapy in genitourinary cancer patients. J Surg Oncol 1981; 16: 111–23

    PubMed  CAS  Google Scholar 

  104. Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985; 56: 1934–9

    PubMed  CAS  Google Scholar 

  105. Melmamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynaecology cancer patients. Cancer 1985; 55: 41–3

    Google Scholar 

  106. Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724–34

    PubMed  CAS  Google Scholar 

  107. Reddel RR, Kefford RF, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of doses and method of drug administration. Cancer Treat Rep 1982; 66: 19–23

    PubMed  CAS  Google Scholar 

  108. Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 1982; 92: 1408–13

    PubMed  CAS  Google Scholar 

  109. Stadnicki SW, Fleischman RW, Schaeppi U, et al. Cis-dichlorodiammineplatinum(II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 1975; 59: 467–80

    PubMed  Google Scholar 

  110. Harpur ES. Ototoxicity: morphological and functional correlations between experimental and clinical studies. In: Ballantyne B, editor. Perspectives in basic and applied toxicology. London: Butterworth and Co, 1988: 42–69

    Google Scholar 

  111. Kohn S, Fradis M, Podoshin L, et al. Toxic effects of cisplatin alone and in combination with gentamicin in stria vascularis of guinea pigs. Laryngoscope 1991; 101: 709–16

    PubMed  CAS  Google Scholar 

  112. Fleischman RW, Stadnicki SW, Ethier MF, et al. Ototoxicity of cis-diamminedichloro platinum(II) in the guinea pig. Toxicol Appl Pharmacol 1975; 33: 320–32

    PubMed  CAS  Google Scholar 

  113. Comis SD, Rhys-Evans PH, Osbourne MP, et al. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of corti. J Laryngol Otol 1986; 100: 1373–83

    Google Scholar 

  114. Nakai Y, Konishi K, Chang KC, et al. Ototoxicity of the anti-cancer drug cisplatin: an experimental study. Acta Otolaryngol 1982; 93: 227–32

    PubMed  CAS  Google Scholar 

  115. Schweitzer VG, Rarey KE, Dolan DF, et al. Ototoxicity of cis-platin vs platinum analogs CBDCA (JM8) and CHIP (JM9). Otolaryngol Head Neck Surg 1986; 94: 458–69

    PubMed  CAS  Google Scholar 

  116. McAlpine A, Johnson BM. The ototoxic mechanism of cis-platin. Hearing Res 1990; 47: 191–204

    CAS  Google Scholar 

  117. Piel IJ, Meyer D, Perlia CP, et al. Effects of cis-diammine-dichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 1974; 58: 871–5

    PubMed  CAS  Google Scholar 

  118. Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 1985; 242: 1–6

    PubMed  CAS  Google Scholar 

  119. Meyer WH, Ayers D, Mchaney VA, et al. Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 1993; 341: 754–5

    PubMed  CAS  Google Scholar 

  120. Kennedy ICS, Fitzharris BM, Colls BM, et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol 1990; 26: 232–4

    PubMed  CAS  Google Scholar 

  121. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1979; 63: 1527–31

    Google Scholar 

  122. Curt GA, Grygiel JJ, Corden BJ, et al. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylato-platinum (NSC241240). Cancer Res 1983; 43: 4470–3

    PubMed  CAS  Google Scholar 

  123. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56

    PubMed  CAS  Google Scholar 

  124. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin- 1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756–61

    PubMed  Google Scholar 

  125. Beijen JH, Van Warmerdam LJC, Huizing MT, et al. Pharmacokinetics of carboplatin in dose finding and sequence study of the combination paclitaxel and carboplatin in non-small cell lung cancer: a European Cancer Centre Study [abstract]. International Symposium On Platinum And Other Metal Coordination Compounds In Cancer Therapy; 1995 Mar 1–4; Amsterdam, 7: 52

    Google Scholar 

  126. Saunders MP, Denton CP, Os’Brien MER, et al. Hypersensitivity reactions to cisplatin and carboplatin: a report of six cases. Ann Oncol 1992; 3: 574–6

    PubMed  CAS  Google Scholar 

  127. Hendrick AM, Simmons D, Cantwell BMJ. Allergic reactions to carboplatin. Ann Oncol 1992; 3: 239–40

    PubMed  CAS  Google Scholar 

  128. Hunter D, Milton R, Perry KMA. Asthma caused by complex salts of platinum. Br J Indust Med 1945; 30: 27–30

    Google Scholar 

  129. Calvert AH, Judson I, Van Der Vijgh WJF. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surveys 1993; 17: 189–217

    PubMed  CAS  Google Scholar 

  130. Bajorin DF, Bosl GJ, Alcock NW, et al. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 1986; 46: 5969–72

    PubMed  CAS  Google Scholar 

  131. Corden BJ, Fine RL, Ozols RF, et al. Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 1985; 14: 38–41

    PubMed  CAS  Google Scholar 

  132. Belt RJ, Himmelstein KJ, Patton TF, et al. Pharmacokinetics of non-protein-bound species following administration of cis-diamminedichloroplatinum(II). Cancer Treat Rep 1979; 63: 1515–21

    PubMed  CAS  Google Scholar 

  133. Van Der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242–61

    PubMed  Google Scholar 

  134. Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984; 44: 1693–7

    PubMed  CAS  Google Scholar 

  135. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedi-carboxylato)platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432–8

    PubMed  CAS  Google Scholar 

  136. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobu-tanedicarboxylatoplatinum. Cancer Res 1985; 45: 6502–6

    PubMed  CAS  Google Scholar 

  137. Newell DR, Pearson ADJ, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosage formula. J Clin Oncol 1993; 11: 2314–23

    PubMed  CAS  Google Scholar 

  138. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573–80

    PubMed  CAS  Google Scholar 

  139. Giandomenico CM, Abrams MJ, Murrer BA, et al. Synthesis and reactions of a new class of orally active Pt(IV) antitumour complexes. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991: 93–100

    Google Scholar 

  140. Van Hennik MB, Van der Vijgh WJF, Klein I, et al. Human pharmacokinetics of carboplatin after oral administration. Cancer Chemother Pharmacol 1989; 23: 126–7

    PubMed  Google Scholar 

  141. Siddik ZH, Boxall FE, Goodard PM, et al. Antitumour, pharmacokinetic and toxicity studies with orally administered cis-platin, CBDCA and CHIP [abstract 1462]. Proc Am Assoc Cancer Res. 1984; 25: 369

    Google Scholar 

  142. McKeage MJ, Morgan SE, Boxall FE, et al. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 1993; 67: 996–1000

    PubMed  CAS  Google Scholar 

  143. McKeage MJ, Boxall F, Jones M, et al. Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994; 54: 629–31

    PubMed  CAS  Google Scholar 

  144. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacological study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol. In Press

  145. McKeage MJ, Morgan SE, Boxall FE, et al. Preclinical toxicology and tissue distribution of novel oral antitumour platinum complexes: ammine/amine platinum (IV) dicarboxylates. Cancer Chemother Pharmacol 1994; 33: 497–503

    PubMed  CAS  Google Scholar 

  146. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993; 53: 2581–6

    PubMed  CAS  Google Scholar 

  147. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an orally administered platinum (Pt) complex (JM216) using a daily x 5 administration schedule [abstract]. Proc Am Soc Clin Oncol 1994; 13: 337a

    Google Scholar 

  148. McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally administered bis-acetato-ammine-dichlorocyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 1994; 54: 4118–22

    Google Scholar 

  149. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989; 43: 237–50

    PubMed  CAS  Google Scholar 

  150. Sekiguchi M, Eriguchi M, Shiroko Y, et al. Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex L-OHP; oxalato(trans-1-1,2-diaminocyclohexane)platinum(II). Ann Oncol 1992; 2: 194a

    Google Scholar 

  151. Boughattas NA, Levi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 1989; 49: 3362–8

    PubMed  CAS  Google Scholar 

  152. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303

    PubMed  CAS  Google Scholar 

  153. Levi F, Misset J, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using a ambulatory multichannel programmable pump: high effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893–900

    PubMed  CAS  Google Scholar 

  154. Schilder RJ, La Creta FP, Perez RP, et al. Phase 1 and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and 8 schedule. Cancer Res 1994; 54: 709–17

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Research Centre, Prince of Wales Hospital and University of New South Wales, High St, Sydney, New South Wales, 2031, Australia

    Mark J. McKeage

Authors
  1. Mark J. McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03257467.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, M.J. Comparative Adverse Effect Profiles of Platinum Drugs. Drug-Safety 13, 228–244 (1995). https://doi.org/10.2165/00002018-199513040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199513040-00003

Keywords

Search

Navigation